Eli Casdin Infuses Synthetic Biology Company with Fresh Capital

In announcing the deal, Casdin noted that “the ability to drive performance and economic advantages through the intelligent engineering of enzymes is now a critical capability across a diverse set of end markets….we believe that Codexis is one of the few proven management teams and technology platforms capable of capturing this fast-growing market demand and are excited to catalyze their strategic growth initiatives.”..